Loading...
XKRX
028300
Market cap4.55bUSD
Jul 15, Last price  
52,000.00KRW
1D
1.19%
1Q
-2.10%
Jan 2017
289.35%
Name

HLB Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
93.51
EPS
—
Div Yield, %
—
Shrs. gr., 5y
5.45%
Rev. gr., 5y
12.14%
Revenues
68.13b
+58.80%
51,641,814,94020,807,717,81037,185,747,89038,460,683,50730,138,866,81423,006,912,16736,185,983,41638,420,748,24556,177,400,69669,825,991,454179,707,913,11242,900,561,19068,125,727,340
Net income
-91.98b
L-51.35%
-5,250,075,860-6,780,075,560-1,481,228,83012,639,604,648-13,214,518,061-16,529,938,42225,342,858,133-44,386,487,974-80,093,074,231-98,125,465,674-78,158,868,867-189,079,377,010-91,980,166,740
CFO
-114.31b
L+2.40%
-891,716,350-4,084,405,290-3,971,900,680527,191,358-10,151,013,868-19,080,875,878-29,162,869,869-48,656,702,381-56,513,635,182-54,765,398,832-61,816,035,433-111,631,653,900-114,312,509,440
Earnings
Aug 12, 2025

Profile

HLB Co., Ltd. manufactures pharmaceutical products, and builds ships. It manufactures and sells various types of lifeboats for marine plants, drill ships, and cruise vessels in South Korea. The company offers conventional type lifeboats, free fall type lifeboats, and rescue boats. It also provides marine and yacht engines; hooks; RIB, patrol, fishing, aluminum, and leisure boats; fishery inspection ships; and safety goods, as well as lifeboat and davit inspection and repair services, service engineering training, and spare parts for lifeboats and davits. In addition, the company develops Riboseranib, a targeted anti-cancer agent; and Apilia that is used for the treatment for ovarian cancer. HLB Co., Ltd. was founded in 1975 and is headquartered in Ulsan, South Korea.
URL
http://www.hlbkorea.com/
IPO date
Jul 27, 1996
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
68,125,727
58.80%
42,900,561
-76.13%
179,707,913
157.37%
Cost of revenue
136,023,146
126,131,497
195,046,858
Unusual Expense (Income)
NOPBT
(67,897,418)
(83,230,936)
(15,338,945)
NOPBT Margin
Operating Taxes
(1,222,342)
(6,753,777)
10,192,611
Tax Rate
NOPAT
(66,675,076)
(76,477,160)
(25,531,556)
Net income
(91,980,167)
-51.35%
(189,079,377)
141.92%
(78,158,869)
-20.35%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,012,888
(4,077,751)
237,605,125
BB yield
-0.02%
0.07%
-7.80%
Debt
Debt current
101,221,867
30,867,671
116,164,006
Long-term debt
75,071,739
47,819,713
13,681,779
Deferred revenue
513,683
13,361,779
Other long-term liabilities
1,596,273
988,410
217,558
Net debt
(234,531,388)
(302,470,005)
(297,409,950)
Cash flow
Cash from operating activities
(114,312,509)
(111,631,654)
(61,816,035)
CAPEX
(19,968,949)
(7,058,823)
(12,627,000)
Cash from investing activities
(74,849,354)
25,534,919
(112,279,852)
Cash from financing activities
170,343,277
(3,048,694)
267,579,356
FCF
(102,615,504)
(29,671,476)
(90,955,792)
Balance
Cash
100,855,191
112,803,605
204,085,709
Long term investments
309,969,803
268,353,784
223,170,025
Excess cash
407,418,707
379,012,361
418,270,339
Stockholders' equity
353,173,533
99,262,646
(205,233,360)
Invested Capital
385,004,880
547,147,881
1,027,885,223
ROIC
ROCE
EV
Common stock shares outstanding
132,057
121,235
112,588
Price
73,100.00
44.18%
50,700.00
87.45%
27,047.62
-22.28%
Market cap
9,653,393,089
57.05%
6,146,635,845
101.84%
3,045,250,586
-27.19%
EV
9,494,407,027
5,902,530,437
2,808,885,294
EBITDA
(61,669,479)
(76,262,602)
986,704
EV/EBITDA
2,846.73
Interest
10,718,531
10,586,054
11,692,170
Interest/NOPBT